Cardiovascular Therapeutics

Aims & Scope

Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies.

Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged.

Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science
• Medline
• PubMed
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine and Pharmacology, Toxicology and Pharmaceutics, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,060.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Relationship between Oxidative Stress and Inflammatory Cytokines in Diabetic Nephropathy

  Citation: 518

  Authors: Ahmed A., Jennifer C.

• REVIEW: Plasminogen Activator Inhibitor‐1 (PAI‐1): A Key Factor Linking Fibrinolysis and Age‐Related Subclinical and Clinical Conditions

  Citation: 350

  Authors: Matteo, Marco, Raffaele Antonelli

• Hypolipidemic, Antioxidant, and Antiinflammatory Activities of Microalgae <i>Spirulina</i>

  Citation: 317

  Authors: Ruitang, Te‐Jin

• Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review

  Citation: 312

  Authors: Rupert, Uwe, Jean-Baptiste, Caroline, Kevin, Maria

• Ticagrelor: The First Reversibly Binding Oral P2Y₁₂ Receptor Antagonist

  Citation: 277

  Authors: Steen, J.J.J.

• The Novel Antioxidant Edaravone: From Bench to Bedside

  Citation: 189

  Authors: Toshiaki, Munenori, Satoru

• Nutraceuticals and Atherosclerosis: Human Trials

  Citation: 164

  Authors: Lina, Gemma, Teresa

• A Novel Hydrogen Sulfide Prodrug, <scp>SG</scp>1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients

  Citation: 154

  Authors: David J., Zhen, Christopher B., Gabriel, Gabriel, Tony, Henry

• Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

  Citation: 150

  Authors: Marsha A.

• The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction

  Citation: 146

  Authors: Pieter, Hanne, Matthias, Pieter, Wilfried